Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$117.99

0.48 (0.41%)

06:49
04/25/19
04/25
06:49
04/25/19
06:49

Eli Lilly facilitating withdrawal of Lartruvo after ANNOUNCE trial failure

Eli Lilly announced that the company has been working to facilitate the withdrawal of Lartruvo from the market for the treatment of advanced soft tissue sarcoma, or STS. Lilly's actions to withdraw Lartruvo from the market follow the failure of the Phase 3 ANNOUNCE clinical trial, in which Lartruvo did not improve survival for patients. Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market. The program will be established as allowed by local country regulations. Lilly is working to ensure that patients who are currently receiving Lartruvo may, in consultation with their physician, continue their course of therapy if they have been informed of the risks of Lartruvo and the results of the ANNOUNCE study and wish to continue, subject to local laws and regulations. No new patients should receive Lartruvo outside of participation in ongoing clinical trials. Lilly also is working to establish a program to allow patients who are currently receiving Lartruvo to continue treatment with limited interruption after Lartruvo is withdrawn from the market, subject to local laws and regulations. More information regarding this program will be provided directly to healthcare professionals in the coming weeks.

  • 25

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

LLY Eli Lilly
$117.99

0.48 (0.41%)

04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/22/19
BMOC
04/22/19
NO CHANGE
Target $130
BMOC
Outperform
Eli Lilly price target lowered to $130 from $134 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.
04/23/19
EDJN
04/23/19
UPGRADE
EDJN
Buy
Eli Lilly upgraded to Buy from Hold at Edward Jones
Edward Jones analyst Ashtyn Evans upgraded Eli Lilly to Buy from Hold.
04/24/19
04/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

11:25
06/20/19
06/20
11:25
06/20/19
11:25
General news
Oil Action: WTI crude advanced as much as 6% »

Oil Action: WTI crude…

QGEN

Qiagen

$41.02

0.34 (0.84%)

11:25
06/20/19
06/20
11:25
06/20/19
11:25
Conference/Events
Qiagen to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Aug

AIR

AAR Corp.

$33.83

0.125 (0.37%)

11:23
06/20/19
06/20
11:23
06/20/19
11:23
Hot Stocks
AAR, Tawazun Economic Council and GAL sign joint repair management deal »

AAR announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GO

Grocery Outlet

$0.00

(0.00%)

11:22
06/20/19
06/20
11:22
06/20/19
11:22
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

11:20
06/20/19
06/20
11:20
06/20/19
11:20
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNLN

Greenlane

$12.23

1.25 (11.38%)

11:19
06/20/19
06/20
11:19
06/20/19
11:19
Recommendations
Greenlane analyst commentary  »

Greenlane fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$47.60

-5.25 (-9.93%)

11:18
06/20/19
06/20
11:18
06/20/19
11:18
Downgrade
Carnival rating change  »

Carnival downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CTST

CannTrust

$5.31

-0.05 (-0.93%)

, CURR

CURE Pharmaceutical

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
On The Fly
Rising High: CannTrust launches U.S. operations with California JV »

In this week's "Rising…

CTST

CannTrust

$5.31

-0.05 (-0.93%)

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CGC

Canopy Growth

$43.05

0.275 (0.64%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

TLRY

Tilray

$47.00

1.55 (3.41%)

IIPR

Innovative Industrial Properties

$135.35

10.335 (8.27%)

ORTFD

Biome Grow

$0.00

(0.00%)

APHA

Aphria

$6.75

0.01 (0.15%)

ACB

Aurora Cannabis

$7.46

-0.025 (-0.33%)

MMNFF

MedMen

$0.00

(0.00%)

ORHOF

Origin House

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

CRON

Cronos Group

$16.50

0.655 (4.14%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.32

0.09 (7.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

NDVAF

INDIVA

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

MRRCF

Wayland Group

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

SNNVF

Sunniva

$0.00

(0.00%)

HMDEF

DionyMed Brands

$0.00

(0.00%)

SRUTF

Sproutly

$0.00

(0.00%)

GRWG

Grow Generation

$0.00

(0.00%)

HRVSF

Harvest Health & Recreation

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/20/19
06/20
11:16
06/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.52

0.23 (0.95%)

11:15
06/20/19
06/20
11:15
06/20/19
11:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Treasury announced a $113 B in coupon sales for next week »

Treasury announced a $113…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BGNE

BeiGene

$124.98

4.98 (4.15%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Hot Stocks
BeiGene announces Phase 1b results of zanubrutinib with Gazyva »

BeiGene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Syndicate
Breaking Syndicate news story on Personalis »

Personalis indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AMRN

Amarin

$19.82

0.4 (2.06%)

11:08
06/20/19
06/20
11:08
06/20/19
11:08
On The Fly
Jefferies sees Amarin stock poised for even more gains »

Seeing the stock's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

STLD

Steel Dynamics

$29.25

-0.45 (-1.52%)

11:05
06/20/19
06/20
11:05
06/20/19
11:05
Options
Steel Dynamics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Hot Stocks
Breaking Hot Stocks news story on Misonix »

Misonix up 39c to $24.17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$5.28

-1.02 (-16.19%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Recommendations
Melinta Therapeutics analyst commentary  »

Gabelli fears Melinta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:03
06/20/19
06/20
11:03
06/20/19
11:03
Hot Stocks
SEC tells Misonix investigation concluded, no enforcement action recommended »

Misonix announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSNL

Personalis

$0.00

(0.00%)

10:59
06/20/19
06/20
10:59
06/20/19
10:59
Syndicate
Personalis indicated to open at $28, IPO priced at $17 »

Personalis (PSNL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AGCO

Agco

$75.20

0.33 (0.44%)

10:57
06/20/19
06/20
10:57
06/20/19
10:57
Conference/Events
Agco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

10:54
06/20/19
06/20
10:54
06/20/19
10:54
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies direct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

VanEck Vectors Gold Miners ETF

$24.79

0.82 (3.42%)

10:50
06/20/19
06/20
10:50
06/20/19
10:50
Options
Recent call buyer in Gold Miners ETF hit the mother lode on Fed stance »

Recent call buyer in Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.